Global Systemic Mastocytosis Market | Data Feature
๐๐ฅ๐จ๐๐๐ฅ ๐๐ฒ๐ฌ๐ญ๐๐ฆ๐ข๐ ๐๐๐ฌ๐ญ๐จ๐๐ฒ๐ญ๐จ๐ฌ๐ข๐ฌ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐๐ซ๐ค๐๐ญ
ะขhะต Glะพbะฐl ะ
ััtะตmัั ะะฐัtะพััtะพััั ะขrะตะฐtmะตnt mะฐrkะตt ัั ะตัtัmะฐtะตd tะพ bะต Uะ
$ 134.5 ะn ัn 2022 ะฐnd ัั expected to reach US$ 222.8 Mn ะฐt ะฐ ะกะGR ะพf 5.8% by 2031.
1. The majority of systemic mastocytosis treatment is readily available in retail pharmacy stores, and the retail pharmacy segment is expected to be fueled by increasing patient footfall throughout the projection period.
2. Due to an increase in the prevalence of systemic mastocytosis in rising countries such as India and China, the market in Asia Pacific is expected to grow at a significantly high rate during the forecast period.
3. The market will be boosted by a rise in research and development expenditures by major pharmaceutical companies to create new treatment options for systemic mastocytosis disorders.
๐๐ข๐ฌ๐๐จ๐ฏ๐๐ซ ๐ฆ๐จ๐ซ๐ ๐ก๐๐ซ๐:
https://datafeature.com/register
-
Category
No comments found